{
    "nct_id": "NCT04249622",
    "official_title": "Phase II Trial of Rifaximin in Patients with Early Stage HER2 Positive Breast Cancer with Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy",
    "inclusion_criteria": "* PRE-REGISTRATION INCLUSION CRITERIA\n* Age >= 18 years\n* Histological confirmation of HER2 positive breast cancer stage I-III per American Joint Committee on Cancer (AJCC) staging 8th edition\n* Provide written informed consent\n* Breast cancer patients who will be receiving pertuzumab-based chemotherapy with either TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab) or docetaxel/paclitaxel, trastuzumab, and pertuzumab\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Hemoglobin >= 10.0 g/dL (obtained =< 30 days prior to pre-registration)\n* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained =< 30 days prior to pre-registration)\n* Platelet count >= 100 x 10^9/L (obtained =< 30 days prior to pre-registration)\n* Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) (obtained =< 30 days prior to pre-registration)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (obtained =< 30 days prior to pre-registration)\n* Serum or plasma creatinine =< 1.5 x ULN (obtained =< 30 days prior to pre-registration)\n* Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula (obtained =< 30 days prior to pre-registration)\n* Negative serum pregnancy test done =< 30 days prior to pre-registration, for person of childbearing potential only\n* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Willingness to provide mandatory stool specimen for correlative research\n* Ability to complete questionnaire(s) by themselves or with assistance\n* REGISTRATION INCLUSION CRITERIA\n* Received pertuzumab based regimens in the adjuvant or neoadjuvant setting\n* Hemoglobin >= 8.0 g/dL (obtained =< 14 days prior to registration)\n* Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (obtained =< 14 days prior to registration)\n* Platelet count >= 100 x 10^9/L (obtained =< 14 days prior to registration)\n* Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) (obtained =< 14 days prior to registration)\n* AST (SGOT)/ALT (SGPT) =< 2.5 x ULN (obtained =< 14 days prior to registration)\n* Serum or plasma creatinine =< 1.5 x ULN (obtained =< 14 days prior to registration)\n* Calculated creatinine clearance >= 45 ml/min using the Cockcroft-Gault formula (obtained =< 14 days prior to registration)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* PRE-REGISTRATION EXCLUSION CRITERIA\n* History of myocardial infarction =< 6 months prior to pre-registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n* Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment\n\n  * EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 3 months since completion of prior treatment\n* Uncontrolled intercurrent non-cardiac illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Psychiatric illness/social situations\n  * Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy\n  * Any other conditions that would limit compliance with study requirements\n* Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm (adjust to protocol if applicable)\n* Any of the following because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown\n\n  * Pregnant women\n  * Nursing women\n  * Women of childbearing potential who are unwilling to employ adequate contraception\n* Current colostomy or ileostomy\n* History of inflammatory bowel disease\n* History of irritable bowel syndrome\n* History of arteriovenous malformations\n* History of gastrointestinal bleeds\n* Previous surgical resection of the small bowel or colon\n* Previous allergy to rifaximin or its derivatives",
    "miscellaneous_criteria": ""
}